Oxford Coronavirus Vaccine
-
{
- All
- News
- Videos
-
Adar Poonawalla's Serum Institute Told To Pause Vaccine Trial Recruitment
New recruitment for the Phase 2 and Phase 3 trials of the Oxford University's Covishield vaccine being manufactured in India by the Serum Institute of India, along with pharma major AstraZeneca, has to be suspended till further orders, country's drug controller DCGI has said.
-
$200-Million Decision To Make Untested COVID-19 Vaccine Took 30 Minutes
The coronavirus vaccine developed at the Oxford University will be in India by November and will ultimately cost Rs 1,000, said the Indian firm partnering the UK researchers. The manufacturing of the Covishield vaccine had started parallelly with the clinical trials, the first phase of which got positive results.
-
Oxford Coronavirus Vaccine Promising, Produces Cell-Mediated Immune Response: Scientists
The coronavirus vaccine developed by Oxford University and pharmaceutical firm AstraZeneca shows promise as it can generate both antibodies and cell-mediated immune responses, say several scientists in India and abroad, while cautioning that there is still a long way to go.
-
Adar Poonawalla's Serum Institute Told To Pause Vaccine Trial Recruitment
New recruitment for the Phase 2 and Phase 3 trials of the Oxford University's Covishield vaccine being manufactured in India by the Serum Institute of India, along with pharma major AstraZeneca, has to be suspended till further orders, country's drug controller DCGI has said.
-
$200-Million Decision To Make Untested COVID-19 Vaccine Took 30 Minutes
The coronavirus vaccine developed at the Oxford University will be in India by November and will ultimately cost Rs 1,000, said the Indian firm partnering the UK researchers. The manufacturing of the Covishield vaccine had started parallelly with the clinical trials, the first phase of which got positive results.
-
Oxford Coronavirus Vaccine Promising, Produces Cell-Mediated Immune Response: Scientists
The coronavirus vaccine developed by Oxford University and pharmaceutical firm AstraZeneca shows promise as it can generate both antibodies and cell-mediated immune responses, say several scientists in India and abroad, while cautioning that there is still a long way to go.
